Role of Endo-opioid and Endo-cannabinoid Systems in Migraine and Medication-overuse Headache
Authors:
Open Access
- 12 January 2023
- journal article
- research article
- Published by Turk Noroloji Dernegi in Turkish Journal Of Neurology
- Vol. 28 (4) , 260-264
Abstract
No abstract availableKeywords
This publication has 40 references indexed in Scilit:
- Effects of anandamide in migraine: data from an animal modelThe Journal of Headache and Pain, 2011
- The endocannabinoid system and migraineExperimental Neurology, 2010
- Nociceptin (1–13)NH 2 Inhibits Stimulated Calcitonin-Gene-Related-Peptide Release From Primary Cultures of Rat Trigeminal Ganglia NeuronesCephalalgia, 2007
- Cannabinoid (CB1) Receptor Activation Inhibits Trigeminovascular NeuronsThe Journal of Pharmacology and Experimental Therapeutics, 2007
- Endocannabinoids in Chronic Migraine: CSF Findings Suggest a System FailureNeuropsychopharmacology, 2006
- Neuronal Signal Substances as Biomarkers of MigraineHeadache: The Journal of Head and Face Pain, 2006
- Biochemical Changes in Endocannabinoid System are Expressed in Platelets of Female but not Male MigraineursCephalalgia, 2006
- Plasma Nociceptin Levels are Reduced in Migraine without AuraCephalalgia, 2005
- Validity and Reliability of the Turkish Migraine Disability Assessment (MIDAS) QuestionnaireHeadache: The Journal of Head and Face Pain, 2004
- Anandamide Is Able to Inhibit Trigeminal Neurons Using an in Vivo Model of Trigeminovascular-Mediated NociceptionThe Journal of Pharmacology and Experimental Therapeutics, 2004